Statements (62)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Pralsetinib
|
| gptkbp:activities |
RET inhibitor
|
| gptkbp:approves |
gptkb:FDA
September 2020 |
| gptkbp:category |
Category D
not recommended |
| gptkbp:clinical_trial |
gptkb:ARROW_trial
Phase 1/2 |
| gptkbp:contraindication |
hypersensitivity to pralsetinib
|
| gptkbp:dissolved |
soluble in DMSO
|
| gptkbp:dosage_form |
gptkb:tablet
|
| gptkbp:duration |
until disease progression
|
| gptkbp:effective_date |
2020-09-04
|
| gptkbp:frequency |
once daily
|
| gptkbp:healthcare |
gptkb:battle
2020-09-04 |
| https://www.w3.org/2000/01/rdf-schema#label |
Gavreto
|
| gptkbp:indication |
RET fusion-positive non-small cell lung cancer
|
| gptkbp:ingredients |
pralsetinib
|
| gptkbp:interacts_with |
strong CY P3 A inducers
strong CY P3 A inhibitors |
| gptkbp:invention |
patented
|
| gptkbp:is_effective_against |
durable responses
prolonged progression-free survival improved response rate |
| gptkbp:is_monitored_by |
electrolytes
blood pressure liver function tests complete blood count |
| gptkbp:is_used_for |
treatment of non-small cell lung cancer
|
| gptkbp:manager |
oral
|
| gptkbp:manufacturer |
gptkb:Blueprint_Medicines_Corporation
|
| gptkbp:marketed_as |
gptkb:Gavreto
|
| gptkbp:packaging |
bottles of 30 tablets
|
| gptkbp:population |
adults
pediatric patients |
| gptkbp:price |
approximately $10,000 per month
varies by insurance |
| gptkbp:provides_information_on |
included in ESMO guidelines
included in ASCO guidelines included in NCCN guidelines |
| gptkbp:research_focus |
targeted therapy
precision medicine oncogenic drivers RET alterations |
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:scholarships |
available through manufacturer programs
|
| gptkbp:side_effect |
fatigue
nausea hypertension diarrhea increased liver enzymes antiemetics for nausea antihypertensives for hypertension liver enzyme monitoring |
| gptkbp:social_structure |
C22 H24 N4 O3 S
|
| gptkbp:storage |
store at 20° C to 25° C
|
| gptkbp:targets |
RET fusion-positive tumors
|
| gptkbp:type_of_care |
important for efficacy
|
| gptkbp:weight |
396.52 g/mol
|